CTD HOLDINGS, INC. (OTCMKTS:CTDH) Files An 8-K Financial Statements and ExhibitsItem 9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit 99.1 |
Complaint, dated November 30, 2017, filed by the Company against the National Institutes of Health in the Unites States District Court for the Northern District of Florida, Gainesville Division |
CTD HOLDINGS INC ExhibitEX-99.1 2 ex_101317.htm EXHIBIT 99.1 ex_101317.htm Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF FLORIDA GAINESVILLE DIVISION ) CTD HOLDINGS,…To view the full exhibit click here
About CTD HOLDINGS, INC. (OTCMKTS:CTDH)
CTD Holdings, Inc. is a biotechnology company. The Company is focused on the use of cyclodextrins in drug development. The United States Food and Drugs Administration has accepted the Type II Drug Master File for its lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin), for filing, as a treatment for Neimann-Pick Type C disease (NPC). NPC is a fatal cholesterol metabolism disease found primarily in children and young adults. It also sells cyclodextrins and related products to the pharmaceutical, nutritional and other industries, primarily for use in diagnostics and specialty drugs. Its product lines include Trappsol, Aquaplex and AP-Flavor. The Trappsol product line includes basic cyclodextrins, and cyclodextrins with various chemical adducts resulting in over 100 various cyclodextrins. The Aquaplex product line includes various cyclodextrins combined with over 80 various ingredients. The AP-Flavor product lines are cyclodextrins that contain various food flavors.
